Decision Resources and Millennium Research Group have released a new report finding that Merck will obtain blockbuster antidiabetic drug sales in the type 2 diabetes market by 2011, thanks to uptake of their DPP-IV inhibitor, Januvia. Januvia will see rapid uptake as a second-and third-line agent in type 2 diabetes treatment and its success will propel Merck into the diabetes market, giving the company 15 percent of the market in 2011. Januvia will become the second-leading blockbuster in the market, behind only Takeda's Actos. Surveyed primary care physicians ranked Merck as best for product innovation.

"The choice of Merck as 'best' for product innovation in type 2 diabetes indicates physicians' enthusiasm for Januvia," said Elena Rossi, analyst at Millennium Research Group. "This enthusiasm is echoed by the 71 percent of surveyed physicians who believe that Merck will be one of the most influential companies in type 2 diabetes over the next five years."

The report also finds that Takeda led the type 2 diabetes drug market in 2006 with a market share of almost 30 percent from sales of the PPAR-gamma agonist Actos; however, this share will fall to about 21 percent in 2011 due to strong competition from the novel DPP-IV inhibitors (like Januvia) and GLP- 1 analogues (such as Eli Lilly/Amylin's Byetta). Nonetheless, the Actos franchise will continue to gain uptake in the market due in part to the launch of a novel fixed-dose combination of Actos with extended-release metformin. Furthermore, Takeda is developing a novel DPP-IV inhibitor, algoliptin, that is expected to launch in the United States and Europe in 2009 and provide strong competition for Januvia.

About Brands & Strategies

Brands & Strategies is the first and only report series to bring together all of the competitive information elements biopharmaceutical companies need to make informed decisions about their products and the best next-steps. Each report includes the following:

  -- Physician perceptions of companies and brand attributes   -- Physician preference for sources of information   -- Physician opinion of future strategies, messaging, and upcoming events   -- Overview of competitive landscape   -- Pipeline analysis by company within a specific disease   -- SWOT analysis on each brand   -- Brand lifecycle strategy, including clinical trial competitive analysis   -- Trend analysis of brand-specific messaging   -- Brand-specific, event-driven, five-year annualized market forecast   -- Country-specific, event-driven market share projections by company and      brand   -- Drug class and brand vs. generics sales by country   -- Pricing analysis with company-specific strategy, price for all drugs      over five years, impact of generics   -- Analysis of promotional spend for each product   -- Selling strategies based on clinical trials   -- Prevalent and diagnosed population by country    About Millennium Research Group 

Millennium Research Group (http://www.mrg.net/), part of the Decision Resources, Inc., family, is a leading provider of strategic information to the healthcare sector. Focused on the medical device, pharmaceutical, and biotechnology industries, the company provides clients its specialized industry expertise through published reports and customized consulting services.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Bayer/Johnson & Johnson's Xarelto Will Drive the Anticoagulant Drug Market to More Than Double by 2016

View Now